scispace - formally typeset
W

Watip Tangjittipokin

Researcher at Mahidol University

Publications -  29
Citations -  182

Watip Tangjittipokin is an academic researcher from Mahidol University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 7, co-authored 17 publications receiving 119 citations.

Papers
More filters
Journal ArticleDOI

Impact of KCNQ1, CDKN2A/2B, CDKAL1, HHEX, MTNR1B, SLC30A8, TCF7L2, and UBE2E2 on risk of developing type 2 diabetes in Thai population.

TL;DR: Of the eight genes included in the analysis, significant association was observed between KCNQ1, CDKN2A/2B, SLC30A8, TCF7L2, and MTNR1B loci and T2D in the Thai study population, and these genes were also significantly associated with anthropometric, glycemic and lipid characteristics.
Journal ArticleDOI

Aberrant mRNA splicing of paired box 4 (PAX4) IVS7-1G>A mutation causing maturity-onset diabetes of the young, type 9

TL;DR: The mutation impaired PAX4 repressor functions on target-gene promoters and increased susceptibility to apoptosis upon high glucose exposure contributes to the pathogenesis of diabetes in this MODY9 family through β-cell dysfunction.
Journal ArticleDOI

PAX4 R192H and P321H polymorphisms in type 2 diabetes and their functional defects

TL;DR: These PAX4 polymorphisms may increase T2D risk by defective transcription regulation of target genes and/or decreased β-cell survival in high glucose condition.
Journal ArticleDOI

Transcription factor 7-like 2 ( TCF7L2 ) variations associated with earlier age-onset of type 2 diabetes in Thai patients

TL;DR: Investigation of the association of five variants at rs7896340, rs7901695,rs7903146, rs12255372, and rs11196205 of TCF7L2 with T2D by high resolution melting analysis found associations between SNP genotype and risk of type 2 diabetes.
Journal ArticleDOI

Novel adiponectin variants identified in type 2 diabetic patients reveal multimerization and secretion defects.

TL;DR: A dominant negative effect of the R131H variant on protein secretion is demonstrated and the possibility of using protein degradation inhibitors as therapeutic agents in the patients carrying adiponectin variants with secretion defect is shown.